106.25 USD
▼-1.69-1.57%
盘后 106.33 +0.08%
2026-09-15
市值
$12.06B
市盈率
31.41
EPS
3.38
股息率
—
52 周区间
61.23 – 111.15
成交量
1.06M
Beta
0.88
目标价
99.56
52W 低 61.2352W 高 111.15
价格走势
公司简介
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...
关联新闻
- Record Revenue Growth Boosts Halozyme Shares
Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.